RCUS ▼ -14.1% - Arcus Biosciences, Inc.
$RCUS - Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
20-OCT-2026 08:37 AM ET
Share this post
More filings for $RCUS
RCUS ▼ -7.0% - Arcus Biosciences, Inc.Oct 20, 2026RCUS ▲ +2.5% - Arcus Biosciences, Inc.Oct 10, 2026RCUS ▼ -5.2% - Arcus Biosciences, Inc.Sep 24, 2026RCUS ▼ -0.0% - Arcus Biosciences, Inc.Sep 22, 2026RCUS ▼ -2.0% - Arcus Biosciences, Inc.Sep 9, 2026RCUS - Arcus Biosciences, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026
View full $RCUS filing history →💬 Comments
Loading comments…
Leave a comment